Treace Medical (NASDAQ: TMCI) CEO adds 52,317 shares in open-market purchases
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
TREACE MEDICAL CONCEPTS, INC. Chief Executive Officer John T. Treace reported open-market purchases of company common stock. He bought 29,430 shares on June 10 at a weighted average price of $4.024 per share and 22,887 shares on June 11 at a weighted average price of $4.0434, totaling 52,317 shares.
The filing notes these prices are weighted averages, with individual trades on June 10 ranging from $3.96 to $4.17 and on June 11 from $3.93 to $4.10. Following these purchases, he directly holds 7,376,150 common shares, including 542,784 restricted stock units. Several trusts and his spouse also hold additional shares indirectly associated with him, but he disclaims beneficial ownership of those holdings.
Positive
- None.
Negative
- None.
Insights
CEO John Treace made modest open-market share purchases, increasing his direct stake.
CEO John T. Treace bought a total of 52,317 TREACE MEDICAL CONCEPTS common shares in open-market transactions around $4 per share. These are straightforward purchases (code P), not option exercises or tax-related dispositions, giving them clearer signaling value than routine compensation entries.
After these trades, he directly owns 7,376,150 shares, which includes 542,784 restricted stock units, indicating a substantial pre-existing position. The filing also lists additional shares held by various trusts and his spouse, but he expressly disclaims beneficial ownership of those indirect holdings. Overall, this appears as a routine, incremental increase rather than a transformational move.
Insider Trade Summary
Net Buyer: 52,317 shares ($210,968)
Net Buy
6 txns
Insider
Treace John T.
Role
Chief Executive Officer
Bought
52,317 shs ($211K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 22,887 | $4.0434 | $93K |
| Purchase | Common Stock | 29,430 | $4.024 | $118K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 7,376,150 shares (Direct, null);
Common Stock — 1,605,000 shares (Indirect, By spouse)
Footnotes (1)
- The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9300 to $4.1000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Includes 542,784 restricted stock units. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9600 to $4.1700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.
Key Figures
June 10 purchase: 29,430 shares at $4.024
June 11 purchase: 22,887 shares at $4.0434
Total shares purchased: 52,317 shares
+3 more
6 metrics
June 10 purchase
29,430 shares at $4.024
Open-market buy of common stock on June 10, 2026
June 11 purchase
22,887 shares at $4.0434
Open-market buy of common stock on June 11, 2026
Total shares purchased
52,317 shares
Net open-market purchases reported in this Form 4
Direct holdings after trades
7,376,150 shares
Common stock directly owned by CEO after June 11, 2026
Included RSUs
542,784 restricted stock units
Portion of CEO’s direct holdings represented by RSUs
Price range June 10
$3.96–$4.17 per share
Range of individual trade prices in June 10 purchase
Key Terms
open-market purchase, weighted average purchase price, restricted stock units, beneficial ownership, +1 more
5 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"The price reported in Column 4 is a weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
restricted stock units financial
"Includes 542,784 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of shares held by his wife"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
trustee financial
"shares held in trust for which he serves as trustee or co-trustee."
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
FAQ
What insider transactions did TMCI CEO John T. Treace report?
John T. Treace reported buying 52,317 shares of Treace Medical Concepts common stock in open-market transactions. He purchased 29,430 shares at $4.024 on June 10 and 22,887 shares at $4.0434 on June 11, according to the Form 4 filing.
Did the TMCI CEO’s Form 4 include any stock option exercises or sales?
The Form 4 for Treace Medical Concepts shows only open-market purchases by the CEO, coded as “P” transactions. There are no reported stock option exercises, tax-withholding dispositions, or share sales in this filing, and the net activity reflects a pure increase in holdings.